18 Jun 12:30 pm

Early-onset bowel cancer: detection and treatment gains

unrecognizable female doctor holding graphic virtual visualization model of intestine organ in hands. multiple virtual medical icons.

18 June, 12:30 - 1:30pm

A diagnosis of colorectal cancer is always life-changing but it is particularly devastating in those under 50. Alarmingly, colorectal cancer is now the leading cause of cancer-related deaths in Australians under the age of 50 years. This seminar will discuss the rising incidence of early-onset colorectal cancer, evolution of screening recommendations, utility of advanced surgical options, and real-world issues unique to people under-50 with colorectal cancer.

The expert panel of speakers includes:
🔹 Assoc. Prof. Eleonora Feletto– Leader of the Gastrointestinal Cancers Policy and Evaluation Stream at the Daffodil Centre. An expert in cancer epidemiology and predictive modelling to understand cancer patterns and outcomes, her work focuses on the prevention and early detection of colorectal and liver cancer both in Australia and abroad.

🔹 Assoc. Prof. Cherry Koh - Colorectal surgeon at RPA Hospital in Sydney. Assoc. Prof Koh is an academic surgeon with an interest in advanced colorectal cancer. She is the associate professor for surgical outcomes and is a part of the Surgical Outcomes Research Centre (SOuRCe) at RPA.

🔹 Dr. Sarah Sutherland - Medical oncologist at Chris O’Brien Lifehouse. Dr Sutherland specialises in the treatment of gastro-intestinal malignancies. She is a senior lecturer at the University of Sydney and after completing a PHD in 2022 on Dendritic Cell vaccine therapy continues to participate in research with a focus on improving outcomes for patients with colorectal cancer.

This NSW Cancer Research Education Seminar will be Chaired by Dr. Alex Flynn - Medical Oncologist (FRACP) and PhD candidate at the University of Newcastle, Hunter Medical Research Institute. Her PhD includes developing clinical evidence to individualise 5FU chemotherapy dosing, so that every patient with colorectal cancer will receive a personalised dose with less side effects and longer survival.



18 June 2024, 12:30 pm

Clinical Themes

Share and Print